Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05480306 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of DKN-01 in Colorectal Cancer
A Phase 2 study, sponsored by Leap Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
NCT05480306 is a Phase 2 study that has completed, run by Leap Therapeutics. The registered enrollment target is 188 participants.
The verdict
NCT05480306, a Phase 2 study, has completed, sponsored by Leap Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
Study Summary
This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) \[FOLFIRI/FOLFOX and bevacizumab\] as second-line treatment of advanced CRC patients.
Interventions
- DRUG Bevacizumab
- DRUG FOLFIRI
- DRUG FOLFOX
- DRUG DKN-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2025-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05480306
The ClinicalTrials.gov registry entry for NCT05480306 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Leap Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT05480306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05480306 about?
NCT05480306 is a clinical study titled "Phase 2 Study of DKN-01 in Colorectal Cancer". This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) \[FOLFIRI/FOLFOX and bevacizumab\] as second-line treatment of advanced CRC patients.
What is the current status of trial NCT05480306?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2022-08-30. Estimated completion is 2025-07-10.
What interventions are being tested in trial NCT05480306?
The interventions under investigation include: Bevacizumab (DRUG), FOLFIRI (DRUG), FOLFOX (DRUG), DKN-01 (DRUG).
Who is sponsoring clinical trial NCT05480306?
This trial is sponsored by Leap Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.